Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Periorbital rejuvenation: Past, present, and next | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) The aesthetic treatment of the periorbital region has evolved significantly, shaped by centuries of innovation and driven by the desire to understand anatomy and how it is affected by aging. Among the earliest documented advancements in…
AAO 2025: Margaret A. Chang, MD, MS, highlights OTX-TKI’s impact on retinal fluid | Ophthalmology Times
Margaret A. Chang, MD, MS, presented updates from the HELIOS Phase 1 trial of OTX-TKI, a sustained-release formulation of the tyrosine kinase inhibitor, axitinib, for the treatment of diabetic retinopathy (DR), at the American Academy of Ophthalmology 2025 annual meeting,…
AAO 2025: Retinal manifestations of antipsychotic medications | Ophthalmology Times
Sharon Fekrat, MD, FACS, FASRS, shared insights at the American Academy of Ophthalmology (AAO) 2025 meeting in Orlando on the retinal manifestations of antipsychotic medications—a topic with important clinical implications for retina specialists. Antipsychotic drugs, used to treat conditions such…
The mechanics of presbyopia: From muscle movement to functional vision | Ophthalmology Times
(Image Credit: AdobeStock) Presbyopia-correcting eye drops share a common mechanism: They are miotic agents designed to create a smaller pupil. The power of the pupil to extend depth of focus is impressive, as observed in patients with smaller pupils who…
Starting from scratch on neovascular age-related macular degeneration | Ophthalmology Times
(Image Credit: AdobeStock) Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value of gene therapy to treat neovascular age-related macular degeneration (nAMD) at the 16th Annual Congress on Controversies…
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy | Ophthalmology Times
A novel topical, incision-free therapy is now approved to help ophthalmologists slow or halt the progression of keratoconus. (Image credit: AdobeStock/Alessandro Grandini) Glaukos recently received FDA approval for its topical, incision-free therapy for keratoconus (Epioxa) that does not require removal…
Dompé’s NAION program selected for FDA Commissioner’s National Priority Voucher Program | Ophthalmology Times
(Image Credit: AdobeStock) Dompé was selected by the US Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of this selection, Dompé has received a voucher granting a significantly shortened review timeline for marketing…
Stoke Therapeutics announces 2-year data from the natural history study, FALCON | Ophthalmology Times
(Image Credit: AdobeStock) Stoke Therapeutics announced 2-year data from the FALCON study, a prospective natural history study in people with autosomal dominant optic atrophy (ADOA). FALCON was a multicenter, 24-month, prospective natural history study of those aged 8 to 60…
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease | Ophthalmology Times
Kenneth C. Fan, MD, MBA, of Retina Consultants of Texas, highlighted findings from the STARLIGHT study at the American Academy of Ophthalmology 2025 annual meeting, held October 18-10, in Orlando, Florida. He focused on the use of MCO-010 optogenetic therapy…
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus | Ophthalmology Times
Glaukos’ FDA-approved Epioxa topical therapy offers a first-of-its-kind, incision-free treatment for patients with keratoconus, according to the company. Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for keratoconus.1,2 This approval…